{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-175477","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.828212+00:00","generated_at":"2026-05-17T17:15:46.740423+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NCCN SCLC guidelines add LEMS testing and amifampridine (FIRDAPSE) treatment recommendation","bullets":["NCCN guidelines for SCLC updated to recommend VGCC antibody testing for LEMS diagnosis.","Amifampridine (FIRDAPSE) added as a supportive care treatment option for LEMS in SCLC.","Approximately 50% of LEMS cases are cancer-associated, most commonly with SCLC.","Catalyst internal analysis suggests 90% of LEMS in SCLC patients may be undiagnosed.","Guideline inclusion could increase clinical awareness and drive adoption of VGCC testing and amifampridine use."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-175477","json":"https://secwatch.observer/filing/0001193125-25-175477.json","markdown":"https://secwatch.observer/filing/0001193125-25-175477.md","text":"https://secwatch.observer/filing/0001193125-25-175477.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525175477/0001193125-25-175477-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525175477/d55613d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:15:46.740423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}